See more : Woongjin Co., Ltd. (016880.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Asensus Surgical, Inc. (ASXC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Asensus Surgical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Eledon Pharmaceuticals, Inc. (ELDN) Income Statement Analysis – Financial Results
- Shenzhen Cheng Chung Design Co., Ltd. (002811.SZ) Income Statement Analysis – Financial Results
- Synlait Milk Limited (SML.NZ) Income Statement Analysis – Financial Results
- Pharma Mar, S.A. (PHMMF) Income Statement Analysis – Financial Results
- Aquis Communications Group, Inc. (AQIS) Income Statement Analysis – Financial Results
Asensus Surgical, Inc. (ASXC)
About Asensus Surgical, Inc.
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.58M | 7.09M | 8.23M | 3.18M | 8.53M | 24.10M | 7.11M | 1.52M | 0.00 | 401.00K | 1.43M | 35.00K | 0.00 | -29.00 | 0.00 | 0.00 | -135.00K | 0.00 | 0.00 | 0.00 | 231.00K | 11.77M | 20.42M | 25.97M | 10.20M | 12.00M | 30.30M | 20.90M | 12.10M | 9.70M | 5.30M | 4.80M | 2.30M | 1.40M |
| Cost of Revenue | 13.61M | 10.87M | 11.10M | 5.17M | 20.73M | 16.17M | 6.73M | 1.07M | 2.19M | 1.10M | 4.81M | 382.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 182.00K | 11.55M | 16.10M | 20.53M | 2.50M | 9.50M | 16.00M | 14.70M | 3.20M | 2.70M | 1.90M | 2.10M | 800.00K | 2.60M |
| Gross Profit | -5.03M | -3.79M | -2.86M | -1.99M | -12.20M | 7.93M | 384.00K | 450.00K | -2.19M | -694.00K | -3.38M | -347.00K | 0.00 | -29.00 | 0.00 | 0.00 | -135.00K | 0.00 | 0.00 | 0.00 | 49.00K | 220.00K | 4.32M | 5.44M | 7.70M | 2.50M | 14.30M | 6.20M | 8.90M | 7.00M | 3.40M | 2.70M | 1.50M | -1.20M |
| Gross Profit Ratio | -58.66% | -53.41% | -34.79% | -62.71% | -143.01% | 32.91% | 5.40% | 29.62% | 0.00% | -173.07% | -236.13% | -991.43% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 21.21% | 1.87% | 21.15% | 20.95% | 75.49% | 20.83% | 47.19% | 29.67% | 73.55% | 72.16% | 64.15% | 56.25% | 65.22% | -85.71% |
| Research & Development | 37.02M | 28.94M | 19.35M | 16.62M | 22.47M | 21.82M | 21.99M | 29.27M | 29.67M | 27.94M | 12.70M | 2.92M | 3.37M | 2.73M | 1.26M | 2.68M | 1.64M | 0.00 | 0.00 | 0.00 | 0.00 | 1.52M | 1.84M | 1.48M | 1.60M | 4.50M | 8.10M | 5.50M | 3.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 19.16M | 20.17M | 19.32M | 14.14M | 18.76M | 13.85M | 12.28M | 10.81M | 7.83M | 6.24M | 4.22M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 16.92M | 14.76M | 13.40M | 13.06M | 28.01M | 25.74M | 17.54M | 9.15M | 2.86M | 1.73M | 1.94M | 3.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.08M | 34.93M | 32.72M | 27.20M | 46.77M | 39.59M | 29.81M | 19.96M | 10.69M | 7.97M | 6.16M | 3.39M | 2.31M | 2.62M | 1.40M | 1.65M | 1.14M | 371.00K | 318.00K | 473.00K | 1.12M | 2.40M | 3.16M | 3.44M | 2.80M | 3.50M | 8.20M | 6.40M | 4.20M | 4.70M | 3.60M | 3.50M | 2.40M | 0.00 |
| Other Expenses | -1.44M | 7.71M | 11.25M | 10.80M | 10.30M | 1.13M | -300.00K | 35.00K | 2.19M | 0.00 | 7.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 4.90M | 3.20M | 1.90M | 1.60M | 1.00M | 1.00M | 800.00K | 400.00K | 400.00K |
| Operating Expenses | 73.10M | 71.58M | 63.32M | 54.62M | 79.54M | 72.28M | 59.66M | 56.20M | 42.54M | 35.92M | 18.86M | 6.31M | 5.67M | 5.35M | 2.66M | 4.33M | 2.77M | 371.00K | 318.00K | 473.00K | 1.12M | 3.93M | 5.00M | 4.92M | 5.60M | 12.90M | 19.50M | 13.80M | 9.30M | 5.70M | 4.60M | 4.30M | 2.80M | 400.00K |
| Cost & Expenses | 86.71M | 82.45M | 74.42M | 59.79M | 100.27M | 88.45M | 66.39M | 57.27M | 42.54M | 37.01M | 23.67M | 6.69M | 5.67M | 5.35M | 2.66M | 4.33M | 2.77M | 371.00K | 318.00K | 473.00K | 1.30M | 15.48M | 21.10M | 25.45M | 8.10M | 22.40M | 35.50M | 28.50M | 12.50M | 8.40M | 6.50M | 6.40M | 3.60M | 3.00M |
| Interest Income | 1.55M | 1.14M | 590.00K | 35.00K | 582.00K | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.00K | 0.00 | 2.00K | 0.00 | 24.00K | 0.00 | 166.00K | 90.00K | 0.00 | 57.00K | 0.00 | 0.00 | 416.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 410.00K | 370.00K | 19.00K | 4.61M | 4.21M | 2.14M | 1.89M | 1.60M | 0.00 | 954.00K | 0.00 | 48.00K | 2.00K | 19.00K | 24.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.73M | 11.08M | 14.11M | 13.70M | 12.47M | 13.29M | 10.34M | 8.91M | 3.43M | 1.31M | 1.48M | 167.00K | 140.00K | 87.00K | 56.00K | 55.00K | 287.00K | -1.00K | 0.00 | 0.00 | 129.00K | 337.00K | 574.00K | 694.00K | 1.20M | 4.90M | 3.20M | 1.90M | 1.60M | 1.00M | 1.00M | 800.00K | 400.00K | 400.00K |
| EBITDA | -74.40M | -64.29M | -50.19M | -47.11M | -133.84M | -48.07M | -135.31M | -122.58M | -46.37M | -35.30M | -20.76M | -13.36M | -5.53M | -5.30M | -2.60M | -5.11M | -2.48M | -372.00K | -318.00K | -473.00K | -940.00K | -3.37M | -108.00K | 1.22M | 3.30M | -5.50M | -2.00M | -5.70M | 1.20M | 2.30M | -200.00K | -800.00K | -900.00K | -1.20M |
| EBITDA Ratio | -867.45% | -895.17% | -609.66% | -1,354.30% | -933.76% | -201.38% | 517.93% | 1,385.78% | 0.00% | -8,802.74% | -1,193.71% | -18,577.14% | 0.00% | 18,268,900.00% | 0.00% | 0.00% | 1,840.00% | 0.00% | 0.00% | 0.00% | -426.84% | -13.71% | -5.30% | -1.73% | 29.41% | -42.50% | -7.26% | -28.71% | 5.79% | 20.62% | -3.77% | -20.83% | -52.17% | -85.71% |
| Operating Income | -78.13M | -75.68M | -64.62M | -60.39M | -154.58M | -49.15M | -61.93M | -123.65M | -46.37M | -36.61M | -25.60M | -6.66M | -5.67M | -5.35M | -2.66M | -4.33M | -2.77M | -371.00K | -318.00K | -473.00K | -1.07M | -3.71M | -682.00K | 525.00K | 2.10M | -10.40M | -5.20M | -7.60M | -400.00K | 1.30M | -1.20M | -1.60M | -1.30M | -1.60M |
| Operating Income Ratio | -910.92% | -1,067.86% | -784.97% | -1,902.02% | -1,811.92% | -203.93% | -870.86% | -8,140.16% | 0.00% | -9,129.43% | -1,789.24% | -19,014.29% | 0.00% | 18,431,000.00% | 0.00% | 0.00% | 2,052.59% | 0.00% | 0.00% | 0.00% | -462.77% | -31.48% | -3.34% | 2.02% | 20.59% | -86.67% | -17.16% | -36.36% | -3.31% | 13.40% | -22.64% | -33.33% | -56.52% | -114.29% |
| Total Other Income/Expenses | 11.00K | 436.00K | 2.38M | -439.00K | -2.75M | -16.00M | -86.17M | -1.85M | -1.60M | -1.04M | -2.75M | 8.35M | -85.00K | -5.30M | 289.00K | -851.00K | -270.00K | 167.00K | 90.00K | 29.00K | 103.00K | -1.68M | 1.28M | 2.09M | 300.00K | -400.00K | 200.00K | 300.00K | 500.00K | 300.00K | 0.00 | 200.00K | 300.00K | 0.00 |
| Income Before Tax | -78.12M | -75.24M | -62.24M | -60.83M | -157.33M | -65.15M | -148.10M | -125.50M | -47.97M | -37.65M | -28.36M | -6.72M | -5.76M | -5.30K | -2.37M | -5.19M | -3.04M | -204.00K | -228.00K | -444.00K | -966.00K | -5.38M | 600.00K | 2.61M | 2.40M | -10.80M | -5.00M | -7.30M | 100.00K | 1.60M | 0.00 | -1.40M | -1.00M | 0.00 |
| Income Before Tax Ratio | -910.80% | -1,061.70% | -756.04% | -1,915.84% | -1,844.16% | -270.33% | -2,082.63% | -8,262.21% | 0.00% | -9,389.53% | -1,981.69% | -19,211.43% | 0.00% | 18,286.21% | 0.00% | 0.00% | 2,252.59% | 0.00% | 0.00% | 0.00% | -418.18% | -45.72% | 2.94% | 10.05% | 23.53% | -90.00% | -16.50% | -34.93% | 0.83% | 16.49% | 0.00% | -29.17% | -43.48% | 0.00% |
| Income Tax Expense | 314.00K | 318.00K | 225.00K | -1.52M | -3.12M | -3.38M | -3.30M | -5.52M | -1.02M | 0.00 | 4.63M | -14.00K | 48.00K | -42.00K | 19.00K | -827.00K | 0.00 | -166.00K | 0.00 | 0.00 | 1.00K | -6.00K | -11.00K | 58.00K | -500.00K | 500.00K | -200.00K | -200.00K | -500.00K | -200.00K | 0.00 | -100.00K | -300.00K | 0.00 |
| Net Income | -78.43M | -75.56M | -62.46M | -59.31M | -154.20M | -61.78M | -144.80M | -119.98M | -46.95M | -37.65M | -28.36M | -6.72M | -5.76M | -5.30M | -2.37M | -5.19M | -3.04M | -204.00K | -228.00K | -444.00K | -967.00K | -5.48M | 611.00K | 2.55M | 2.60M | -10.90M | -5.00M | -7.40M | 100.00K | 1.50M | -1.20M | -1.50M | -1.00M | -1.60M |
| Net Income Ratio | -914.46% | -1,066.19% | -758.77% | -1,868.09% | -1,807.54% | -256.31% | -2,036.23% | -7,898.62% | 0.00% | -9,389.53% | -1,981.69% | -19,211.43% | 0.00% | 18,286,200.00% | 0.00% | 0.00% | 2,252.59% | 0.00% | 0.00% | 0.00% | -418.61% | -46.52% | 2.99% | 9.83% | 25.49% | -90.83% | -16.50% | -35.41% | 0.83% | 15.46% | -22.64% | -31.25% | -43.48% | -114.29% |
| EPS | -0.31 | -0.32 | -0.28 | -0.84 | -8.69 | -3.88 | -0.97 | -1.07 | -0.59 | -0.64 | -2.23 | -6.24 | -1.03 | -1.19 | -0.66 | -1.51 | -1.19 | -0.06 | -0.30 | -0.90 | -2.11 | -11.95 | 1.35 | 5.60 | 5.70 | -23.89 | -11.10 | -16.82 | 0.23 | 4.00 | -3.50 | -5.00 | -51.59 | -6.50 |
| EPS Diluted | -0.31 | -0.32 | -0.28 | -0.84 | -8.69 | -3.88 | -0.97 | -1.07 | -0.59 | -0.64 | -2.23 | -6.24 | -1.03 | -1.19 | -0.66 | -1.51 | -1.19 | -0.06 | -0.30 | -0.90 | -2.11 | -11.95 | 1.35 | 5.45 | 5.65 | -23.89 | -11.10 | -16.82 | 0.23 | 3.50 | -3.50 | -5.00 | -51.59 | -6.50 |
| Weighted Avg Shares Out | 249.69M | 236.49M | 226.96M | 70.81M | 17.74M | 15.94M | 148.74M | 112.19M | 79.63M | 58.71M | 12.73M | 1.08M | 5.60M | 4.45M | 3.59M | 3.44M | 2.55M | 3.21M | 756.00K | 494.00K | 458.40K | 458.40K | 458.40K | 457.40K | 456.40K | 456.20K | 450.45K | 439.98K | 400.00K | 375.00K | 342.86K | 300.00K | 19.38K | 246.15K |
| Weighted Avg Shares Out (Dil) | 249.69M | 236.49M | 226.96M | 70.81M | 17.74M | 15.94M | 148.74M | 112.19M | 79.63M | 58.71M | 12.73M | 1.08M | 5.60M | 4.45M | 3.59M | 3.44M | 2.55M | 3.21M | 756.00K | 494.00K | 458.40K | 458.40K | 460.40K | 467.80K | 458.40K | 456.20K | 450.45K | 439.98K | 400.00K | 428.57K | 342.86K | 300.00K | 19.38K | 246.15K |
Asensus Surgical Announces Closing of Acquisition by KARL STORZ
KARL STORZ acquires US-headquartered company to create a surgical robotics hub and drive Perfomance-Guided Surgery™ KARL STORZ acquires US-headquartered company to create a surgical robotics hub and drive Perfomance-Guided Surgery™
Asensus Surgical (ASXC) Reports Q2 Loss, Tops Revenue Estimates
Asensus Surgical (ASXC) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.
Asensus Surgical, Inc. (ASXC) Q2 2024 Earnings Call Transcript
Asensus Surgical, Inc. (NYSE:ASXC ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Mark Klausner - IR, Westwicke Partners Anthony Fernando - President and CEO Shameze Rampertab - CFO Conference Call Participants Operator Good afternoon,...
Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 13, 2024
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024...
Asensus Surgical 2024 Special Meeting of Stockholders Is Adjourned
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced that the Company's Special Meeting of Stockholders, scheduled to be held...
Independent Proxy Advisory Firm ISS Recommends Asensus Surgical Stockholders Vote “FOR” the Pending Merger with KARL STORZ
RESEARCH TRIANGLE PARK, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”),...
Glass Lewis Recommends Asensus Surgical Stockholders Vote “FOR” Proposals Relating to Proposed Merger with KARL STORZ
RESEARCH TRIANGLE PARK, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced today that a leading independent proxy advisory firm, Glass, Lewis & Co....
Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology
RESEARCH TRIANGLE PARK, N.C., July 23, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced that it has received 510(k) clearance from the U.S. Food and...
Asensus Surgical Announces LKH-Universitätsklinikum Graz Hospital in Austria to Initiate Senhance Surgery Program
RESEARCH TRIANGLE PARK, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, announced that LKH-Universitätsklinikum Graz in Austria has entered into an agreement...
Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance
Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System.
Source: https://incomestatements.info
Category: Stock Reports